PVG.L Regulatory News (PVG)

PREMIER VETERINARY GROUP PLC

EXERCISE OF WARRANTS

TOTAL VOTING RIGHTS

BLOCK LISTING APPLICATION

Exercise of warrants

London, 28 March 2017: Premier Veterinary Group plc (LSE: PVG) (the "Company") announces that it has received notice of exercise of warrants from WG Partners LLP to subscribe for 139,517 ordinary shares of 10 pence each ("ordinary shares") at a price of 12.6 pence per share. Warrants over 279,034 ordinary shares were granted to WG Partners LLP as part of the arrangements relating to the reverse acquisition by the Company of Premier Veterinary Group Limited (now PVG 2007 Limited) completed in February 2015. Following the exercise of these warrants, there are no further warrants outstanding.

Application has been made to the London Stock Exchange for the admission of 139,517 new ordinary shares to the Official List of the UK Listing Authority and to trading on the London Stock Exchange's market for listed securities ("Admission"). Admission is expected to occur on or around 30 March 2017. The new ordinary shares will rank pari passu with the existing ordinary shares in the Company.

Total voting rights

Following Admission, the Company's enlarged issued share capital will comprise 15,046,950 ordinary shares. The Company does not hold any shares in treasury. The figure of 15,046,950 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Block Listing Application

The Company further announces that it has made a block listing application to the London Stock Exchange for the admission of 120,000 ordinary shares to the Official List of the UK Listing Authority and to trading on the London Stock Exchange's market for listed securities upon issuance.

These 120,000 shares are being reserved under block listings in respect of ordinary shares to be issued under the Company's share option plans and represent:

· an increase of 90,000 ordinary shares in respect of an existing block listing for the 2014 Ark Therapeutics Group plc* Enterprise Management Incentive Share Option Plan; and

· a new block listing of 30,000 ordinary shares in respect of the 2014 Ark Therapeutics Group plc* Unapproved Share Option Plan

(together the "Plans").

Shares issued pursuant to the exercise of options under the Plans will rank pari passu with the existing ordinary shares.

It is expected that the block admission will become effective on 30 March 2017.

* Premier Veterinary Group plc was formerly known as Ark Therapeutics Group plc

Enquiries:

Premier Veterinary Group plc

Will Evans, Chief Financial Officer +44 (0)117 370 0300